Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella

Figure 3

The S2-Ag85A oral vaccine attenuates toxicity in mice. (a) The bacterial content in the spleen was measured at the 1st, 3rd, 5th, 7th, 9th, and 11th week after the completion of vaccination, and the bacterial content showed significantly lower in the mice-spleen of the S2-Ag85A group than that in the S2 group at the 9th week and 11 weeks ( value < 0.05). (b) Determination of the spleen weight at the 1st, 3rd, 5th, 7th, 9th, and 11th weeks after the vaccination; the spleen of mice in the S2 group was swollen at the 1st, 3rd, and 5th week, and the weight elevated with a significant level (), and then gradually, it returned to normal; the similar weight of mice spleen was found in the S2-Ag85A and Ag85A groups. value < 0.05, compared with the S2 group.

(a)

(b)